Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer

Even though antithrombotic therapy (ATT) probably has little or even negative effect on the well-being of patients with cancer near the end of life, it is often continued until death, possibly leading to excess bleeding complications, increased disease burden, reduced quality of life and higher heal...

Ausführliche Beschreibung